Clinical Trials Logo

Filter by:
NCT ID: NCT03296371 Active, not recruiting - Clinical trials for Embryonal Rhabdomyosarcoma

Genetic Mutational Analysis of Saliva or Buccal Mucosa Samples From Patients With Embryonal or Alveolar Rhabdomyosarcoma

Start date: October 23, 2017
Phase:
Study type: Observational

This research trial studies genetic mutations in saliva or buccal mucosa samples from patients with embryonal or alveolar rhabdomyosarcoma. Identifying gene mutations may help doctors learn about the prognosis of patients with embryonal or alveolar rhabdomyosarcoma.

NCT ID: NCT03295734 Active, not recruiting - Hypertension Clinical Trials

ACES - ACE Inhibitors Combined With Exercise for Seniors With Hypertension

ACES
Start date: May 29, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this project is to conduct a randomized, controlled trial (RCT) to determine if choice of antihypertensive medication influences changes in functional status and other cardiovascular risk factors among older persons with hypertension when combined with physical exercise.

NCT ID: NCT03295396 Active, not recruiting - Glioma Clinical Trials

ONC201 in Adults With Recurrent H3 K27M-mutant Glioma

Start date: October 31, 2017
Phase: Phase 2
Study type: Interventional

The primary objective of this phase II trial is to determine the efficacy and safety of ONC201, an oral small molecule imipridone DRD2 antagonist, in adult subjects with recurrent high-grade glioma. This study will test the research hypothesis that histone H3 K27M mutation sensitizes to oral administration of ONC201 in gliomas.

NCT ID: NCT03295279 Active, not recruiting - Lung Cancer Clinical Trials

WTC Chest CT Imaging Archive

Start date: September 1, 2012
Phase:
Study type: Observational

Dr. Rafael E de la Hoz and colleagues have performed standardized and computer-assisted readings of all chest CT scans received by WTC workers and volunteers at the Mount Sinai Medical Center between 2003 and 2016. The clinical team sought to assess all findings suggestive of airway, interstitial, and neoplastic disease in a systematic way, and correlate those findings with clinical, functional, and exposure indicators. The study team's research will also involve analyses of longitudinal imaging and functional trends, and characterization of the WTC related lower airway diseases and their risk factors, with a focus on obesity-related imaging markers. The study team also plans to characterize the transitions into chronic obstructive pulmonary disease (COPD) among these workers.

NCT ID: NCT03294759 Active, not recruiting - Clinical trials for ACL - Anterior Cruciate Ligament Rupture

Bio ACL Reconstruction Amnion Collagen Matrix Wrap and Stem Cells

BioACLRCT
Start date: September 6, 2017
Phase: N/A
Study type: Interventional

Collagen based -membrane derived from amniotic tissue can be used to help reestablish the natural synovial lining of the reconstructed ACL, in effect acting as both a barrier from the synovial fluid and as a scaffold to contain autologous mesenchymal stem cells and growth factors contiguous with the graft, thus aiding and perhaps accelerating the natural maturation and ligamentization process of the implanted graft tissue. Acceleration and improvement in graft maturation and strength would be a significant advancement in sports medicine allowing safer and earlier return to sports and activity

NCT ID: NCT03294083 Active, not recruiting - Clinical trials for Renal Cell Carcinoma

A Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal Cell Carcinoma

Start date: June 7, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1b/2a, open-label, multi-center, dose-escalation and safety/efficacy evaluation trial of Pexa-Vec plus Cemiplimab in patients with metastatic or unresectable renal cell carcinoma (RCC). The trial consists of a dose-escalation stage, where the maximum feasible dose of Pexa-Vec in combination with Cemiplimab will be determined, followed by an expansion stage. During the expansion patients will receive Cemiplimab alone or in combination with Pexa-Vec, which will be administered either through intravenous (IV) or intratumoral (IT) injection.

NCT ID: NCT03293524 Active, not recruiting - Clinical trials for Leber Hereditary Optic Neuropathy

Efficacy & Safety Study of Bilateral IVT Injection of GS010 in LHON Subjects Due to the ND4 Mutation for up to 1 Year

REFLECT
Start date: March 12, 2018
Phase: Phase 3
Study type: Interventional

The goal of this clinical trial is to assess the safety and efficacy of GS010, a gene therapy, in improving the retina functional & structural outcomes in subjects with LHON due to the G11778A ND4 mitochondrial mutation when vision loss duration is present up to one year.

NCT ID: NCT03292926 Active, not recruiting - Clinical trials for Anterior Cruciate Ligament Injury

A Novel Analgesia Technique for ACL Reconstruction

Start date: October 4, 2017
Phase: Phase 4
Study type: Interventional

A comparison of two anesthetic techniques-- the Adductor Canal Block (ACB) and the Adductor Canal Block with Infiltration of the interspace between the popliteal artery and the capsule of the posterior knee (ACB/IPACK)-- in patients undergoing bone-tendon-bone (BTB) anterior cruciate ligament (ACL) reconstruction.

NCT ID: NCT03292458 Active, not recruiting - Spasmodic Dysphonia Clinical Trials

Sodium Oxybate in Spasmodic Dysphonia and Voice Tremor

Start date: January 22, 2018
Phase: Phase 2/Phase 3
Study type: Interventional

Using a comprehensive approach of clinico-behavioral testing, neuroimaging and pharmacogenetics, the researchers will examine the clinical effects of sodium oxybate and the matched placebo on voice symptoms in spasmodic dysphonia and voice tremor.

NCT ID: NCT03292198 Active, not recruiting - Clinical trials for Breast Cancer-related Subclinical Lymphedema

Subclinical Lymphedema Treatment Study

SLT
Start date: April 1, 2018
Phase: N/A
Study type: Interventional

Primary Objective - To compare the effectiveness of 2 treatment protocols for patients with breast cancer-related subclinical lymphedema identified through bioimpedance spectroscopy, L-dex scores Secondary Objectives - To determine the necessary duration of intervention to reverse L-dex scores back to a normal range in patients with breast cancer-related subclinical lymphedema - To determine the time elapsed post-surgically to the development of subclinical lymphedema identified by bioimpedance spectroscopy, L-dex scores - To identify risk factors for the development of subclinical lymphedema in patients with breast cancer - To identify factors associated with the progression to clinical lymphedema following treatment of subclinical lymphedema as identified by bioimpedance spectroscopy, L-dex scores Women with breast cancer diagnoses and planned axillary lymph node procedures will receive pre-operative screening of arm volume with bioimpedance, which will capture baseline measurements. Then, subjects will undergo periodic screenings for the first 3 years following surgery. If a significant change in volume compared to baseline is detected with bioimpedance, subjects will be randomized to 1 of 2 treatment groups. The outcomes of 2 treatment protocols will be compared. Additionally, subjects will be screened each week during their treatment interventions to determine the necessary quantity of intervention before L-dex scores normalize.